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Abstract
Background: Cervical carcinoma (CC) is one of the most common cancers among women
worldwide and the first cause of death among the Mexican female population. CC progression
shows a continuum of neoplastic transitions until invasion. Matrix metalloproteinases (MMPs) and
cathepsins play a central role on the enhancement of tumor-induced angiogenesis, cell migration,
proliferation, apoptosis and connective tissue degradation. MMPs -2 and -9 expression has been
widely studied in cervical cancer. Nevertheless, no other metalloproteinases or cathepsins have
been yet related with the progression and/or invasion of this type of cancer.
Methods: Three HPV18 CC cell lines, two HPV16 CC cell lines and three HPV16 tumor CC
tissues were compared with three morphologically normal, HPV negative, cervical specimens by
cDNA arrays. Overexpression of selected genes was confirmed by end point semiquantitative
reverse transcription-PCR with densitometry. In situ hybridization and protein expression of
selected genes was further studied by means of two tissue microarrays, one consisting of 10 HSIL
and 15 CC and the other one of 15 normal cervical and 10 LSIL tissues.
Results: TIMP1, Integrins alpha 1 and 4, cadherin 2 and 11, Cathepsins F, B L2, MMP 9, 10 11 and 12
were upregulated and Cathepsin S, L, H and C, Cadherins 3 and 4, TIMP3, MMP 13, Elastase 2 and
Integrin beta 8 were found to be downregulated by cDNA arrays. Endpoint RT-PCR with
densitometry gave consistent results with the cDNA array findings for all three genes selected for
study (CTSF, MMP11 and MMP12). In situ hybridization of all three genes confirmed overexpression
in all the HSIL and CC. Two of the selected proteins were detected in LSIL, HSIL and CC by
immunohistochemistry.
Conclusion: Novel undetected CC promoting genes have been identified. Increased transcription
of these genes may result in overexpression of proteins, such as CTSF, MMP11 and MMP12 which
could contribute to the pathogenesis of CC.
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Background
Cervical carcinoma (CC) is one of the most common can-
cers among women worldwide and the first cause of death
among the Mexican female population[1]. High-risk
human papillomavirus (HPV) infection is considered the
most important risk factor associated with the develop-
ment of this tumor, and it is present in the 99.7% of inva-
sive cervical tumors worldwide[2]. CC progression shows
a continuum of neoplastic transitions from low grade
squamous intraepithelial lesion (LSIL), High grade squa-
mous intraepithelial lesion (HSIL), to invasive cervical
cancer. Tumor invasion and metastasis are key steps in the
progression of malignant tumors, which involves both
extracellular matrix (ECM) and basement membrane deg-
radation[3]. Although several classes of proteolytic
enzymes are involved in these processes[4], Matrix metal-
loproteinases (MMPs) play a central role on the enhance-
ment of tumor-induced angiogenesis, cell migration,
proliferation, apoptosis and connective tissue degrada-
tion [5,6]. Different MMP family members have been
identified, including collagenases (MMP-1, -8 and -13),
gelatinases (MMP-2 and -9), stromelysins (MMP-3, -10, -
11), membrane associated (MMP-14, -15, -16, -17, -23, -
24, -25) and other types of MMPs, such as the Metal-
loeslastase (MMP-12)[7]. MMPs -2 and -9 have been
widely studied. Increased mRNA and protein levels of
both MMP-2 and MMP-9 have been detected in breast,
colon, pancreatic and cervical cancers[8].
Human macrophage metalloelastase (MMP-12) has been
identified in alveolar macrophages of cigarette smokers as
an elastolytic MMP[9]. It can degrade elastin, and other
substrates, such as type IV collagen, fibronectin, laminin,
gelatin, vitronectin, entactin, heparin, and chondroitin
sulphates[10]. MMP-12 is overexpressed by macrophages
in atherosclerotic lesions[11] and in intestinal ulcera-
tions[12]. It has been demonstrated that besides macro-
phages, transformed epithelial cells can express MMP-12
in skin and vulvar cancers; MMP12 expression levels cor-
relate with epithelial dedifferentiation and histological
aggressiveness [13,14].
Stromelysin 3 ST3 (MMP-11) is another protease that can
modulate cancer progression by remodelling extracellular
matrix. It cleaves α 1-antitripsin and IGF-BP1[15]. Normal
ST3 expression is present during embriogenesis and
wound healing, and its expression in stressed epithelial
cells is detected in the vicinity of fibroblasts[16]. Malig-
nant epithelial cells depend on local stromal cells includ-
ing fibroblastic, endothelial and inflammatory cells to
develop primary and secondary tumors. ST3 expression is
observed in the area which surrounds malignant epithe-
lial tumour cells and sometimes in tumor cells of esopha-
geal, oral, papillary thyroid, colorectal, skin and ovarian
carcinomas [17-22]. Hence, ST3 gene expression appears
to be associated with tumor progression[23].
Cathepsins are cysteine proteases from the papain family
that are responsible for protein breakdown in lysosomes.
The human Cathepsin family is composed by Cathepsins
B, C, F, H, K, L, O, S V, W and X[24]. The recently
described Cathepsin F has been demonstrated by North-
ern blot analysis, to be ubiquitously expressed in several
tissues with a higher expression in skeletal muscle and tes-
tis. Cathepsin F transcripts were also found in several can-
cer cell lines, suggesting that this enzime could be
involved in degradative processes during tumor
progression[25].
In the present study we examined mRNA expression levels
of 8,000 genes including MMPs and cathepsins by means
of cDNA microarrays in CC samples and cell lines.
Selected genes were confirmed to be up-regulated by end-
point RT-PCR and densitometry. Moreover, RNA and pro-
tein expression of the selected genes were further
examined by in situ hybridization and IHC applied on Tis-
sue Microarrays (TMAs)[26]. Several genes that were
either up- or down-regulated in CC were detected, raising
the possibility that these genes could play an active or a
passive role in the malignant progression of CC.
Methods
Cell lines and tissue samples for cDNA arrays and RT-PCR
Hela (HPV18), SiHa (HPV16) and CaSki (HPV16) cell
lines were grown in the recommended media. The cell
lines designated CaLO (derived from Invasive squamous
carcinoma Stage IIB, HPV18) and INBL (derived from
Invasive Squamous carcinoma IV A, HPV18), were estab-
lished at the FES Zaragoza-UNAM, Mexico [27]. Fresh
biopsies of dysplastic lesions were taken during colpos-
copy from 20 patients at the National Center for Dyspla-
sias, in Mexico City. Twenty two normal cervical tissues
from pre-menopausal women who died from non-gyne-
cological related causes were obtained within the first two
hours  post-mortem  at the Pathology Department of the
Hospital General de Mexico, S. S. All the described proce-
dures were evaluated and approved by the local commit-
tee of ethics of the Mexican Institute of Social Security; we
also obtained written informed consent from the patients.
All tissue samples were divided in three sections, the cen-
tral part was snapped frozen in liquid nitrogen and stored
at -70°C until nucleic acid extraction, and the extremes
from the biopsies were fixed overnight in 70% ethanol
and paraffin embedded at the Department of Pathology,
Oncology Hospital, National Medical Center SXXI, Mex-
ico. Serial sections from the extremes of the biopsies
stained by Haematoxilin/Eosin were inspected for repre-
sentativity of the tissue. Carcinoma samples were consid-
ered as representative when at least 70% of all cells in theBMC Cancer 2005, 5:68 http://www.biomedcentral.com/1471-2407/5/68
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tissue section consisted of cancer cells. Normal tissue sam-
ples were considered as such when at least 80% of the
sample consisted of microscopically ectocervical normal
tissue and HPV infection absence. All the invasive samples
were diagnosed as squamous lesions.
Tissue samples for ISH and IHC
Paraffin blocks of 35 patients: 10 HSIL, 15 CC, and 10
LSIL were randomly collected from the files of the
National Center of Dysplasias in Mexico City. Fifteen nor-
mal cervical tissue samples (obtained post-mortem) were
fixed in buffered formaldehyde and embedded in paraffin
for preparation of the TMA blocks. The TMAs were con-
structed as previously described[28]. One of the TMAs
contained 10 HSIL tissues and CC samples; the other was
made with the 15 normal cervical tissues and 10 LSIL sam-
ples. The TMAs did not include the investigated samples
by the cDNA arrays or by RT-PCR.
Nucleic acid isolation for probe preparation and RT-PCR
Both RNA and DNA were Isolated from all tissue samples
which met the required criteria: squamous cell carcinoma,
HPV type 16 or 18, at least 70% cancer cells in the biopsy,
and from the cervical cancer cell lines using the Trizol Rea-
gent (Gibco BRL, Life Technologies, Grand Island NY
USA) according to manufacturer's conditions. Each DNA
sample was subjected to HPV typing by polymerase chain
reaction (PCR) using the MY09/MY11 consensus primers
and direct sequencing. Potentially contaminating DNA
was removed by RNAse-free DNAse I treatment (Ambion
Inc. Austin Texas USA). The resulting RNA concentration
was measured spectrophotometrically and the quality of
both nucleic acids was confirmed in agarose gels.
cDNA probe preparation
cDNAs were synthesized according to Ambion Advantage
System User Manual. These samples were: cell lines HeLa,
SiHa, CaSki, CALO and INBL, three HPV16+ tumor sam-
ples (T07, T31, T64) and three HPV- normal samples
(N03, N11, N22). Unfortunately no HPV18+ tumor sam-
ples were available for array hybridization due to insuffi-
cient RNA yield for probe preparation. The cDNA probes
were obtained by RT-PCR from 500 ng RNA in the pres-
ence of (α -33P) dATP (3000 Ci/mmol, NEN). Briefly,
RNAs were denatured at 70°C for 10 min and cDNAs were
synthetized at 42°C by oligo-dT priming in a final volume
of 30 µl. The labelled cDNAs were purified by spin col-
umn chromatography. The final incorporation of the radi-
olabel was approximately 1 × 108 cpm per reaction.
Hybridization and array analysis
ULTRArray Advantage System array blots (Ambion Inc.
Austin Texas USA) containing 8400 genes were prehybrid-
ized at 68°C for at least 90 min before probe addition in
hybridization buffer. Then, 1.5 × 107 cpm of each labeled
cDNA was added to the buffer. Hybridization was per-
formed at 60°C overnight in a rolling bottle. The arrays
were washed twice with 2X SSC and 0.5 % SDS at 60°C for
30 min; followed by two stringent washes with 0.5X SSC,
0.5% SDS at the same temperature and for the same
length of time. Finally, damp arrays were sealed in plastic
wrap and exposed to imaging plates (BASMP 2040S; Fuji,
Nakamura, Japan) for 24 hours, which were then scanned
with a STORM 860 phosphorimager/fluorimager (Amer-
sham Biosciences, Buckinghamshire UK) to obtain 16-bit
images. ArrayVision software (Image Research Inc) was
used for the analysis. The artifacts were eliminated and the
intensity of each spot was analyzed after background sub-
straction. Then, data was normalized and analyzed by
using limma bioconductors and marray package [29,30]
for all genes presented in the array and the means of the
normal array (three normal samples) were obtained. The
frequency of positive cases was obtained by comparing
the mean normal array with each individual tumor or cell
line array. The threshold frequency was set at 40% and the
intensity ratio (tumor;normal) threshold values of 4 up-
regulation and -1 for down-regulation present in all sam-
ples were used in an attempt to detect significant expres-
sion changes.
RT-PCR analysis
Estimation of the reliability of the cDNA results for the
three selected genes was performed by endpoint RT-PCR
with densitometry. These samples were previously
described; four normal samples, 5 cell lines, 3 HPV16 and
2 HPV18 tumors; displaying a clear change in their expres-
sion in respect to the normal, independently of the HPV
type present. Two-hundred ng of total RNA from all sam-
ples were reverse transcribed using the RT-PCR Access Sys-
tem (Promega, Madison, WI). Primers for the genes of
interest were: Cathepsin F (CTSF) 396 bp, TM = 67°C, (5'-
GTGCTGATCAGAGTGGCTGCTGC-3' and 5'-AGTTTCCY-
GGACATGGAGAGGGAC-3'); Matrix Metalloproteinase
12 (MMP12), 370 bp TM = 55°C (5'-TCACGAGATT-
GGCCATTCCTT-3' and 5'-TCTGGCTTCAATTTCATAAGC-
3')[31]; and Matrix Metalloproteinase 11 (MMP11/
STMY3), 399 bp, TM = 66°C, (5'-CCATGGCAGTTGGT-
GCAGGAGCAG-3' and 5'-TGCAGTCATCTGGGCTGA-
GACTCA-3'); and β -actin: (5'-
TGAAGTCTGACGTGGACATC-3' and GTTCGTTCCTCAT-
ACTGCTCA-3') 243 bp, TM = 55°C primers were
designed using Integrated DNA technologies Biotools
software http://biotools.idtdna.com/gateway. The RT-
PCR conditions were: for the first strand synthesis of
cDNA 48°C for 45 min and 94°C for 2 min to denature
template; and for second strand synthesis and DNA
amplification: 94°C for 30 sec, (specific TM°C for each set
of primers) for 1 min, and 68°C for 2 min for a total of 24
cycles, followed by a single step at 68°C for 7 min. The
products were visualized on 1.5% agarose gels stainedBMC Cancer 2005, 5:68 http://www.biomedcentral.com/1471-2407/5/68
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with ethidium bromide, and signals were quantified by
densitometry using MetaView analysing system (version
4.5 Universal Imaging Corp., USA). MMP11, MMP12 and
CTS  expression was standardized to β -actin expression
assessed from the same cDNA in separate PCR reactions
and run in parallel on separate gels. The standardized
mean of each triplicate PCR was then expressed relative to
the levels in β -actin cDNA. Statistical comparisons among
groups were analyzed by a Kruskall Wallis-test. A P value
of <0.05 was considered as statistically significant.
In situ hybridization (ISH)
Briefly, five-micron tissue sections were obtained from
TMA paraffin blocks, deparaffinized and rehydrated in a
graded ethanol series (100, 90, 70, and 30%), and trans-
ferred to PBS solution (137 mM NaCl, 2.7 mM KCl, 4.3
mM Na2HPO4, 1.4 mM KH2PO4) for 10 min. Tissues were
treated with DNase solution (1 µg/ml) for 10 min at 37°C
and washed three times in PBS. Endogenous peroxidase
inactivation was carried out by incubating the samples in
hydrogen peroxide in methanol for 3% hydrogen perox-
ide (H2O2) for 40 min. Sense and antisense probes for
CTSF, MMP11 and 12 genes were generated by single-
strand PCR using specific cDNA obtained from SiHa cells
RNA as template and labeled with biotin-16-dUTP
(Roche). Each tissue was covered with 50 µl hybridization
cocktail and a coverslip. The hybridization cocktail con-
sisted of 50% formamide, 10% dextran sulfate, 2X SSC
(20X SSC: 3 M NaCl, 300 mM Na3C6H5O7), PBS, 2% SDS,
100 µg/ml sonicated salmon sperm and 50 ng of dUTP-
biotin-labeled probe (sense or antisense). Both the tissue
RNA and probe were denatured at 65°C for 10 min. After
hybridization, the coverslips were soaked off in Tris-buff-
ered saline with Tween buffer 1X (TBST 10X: 500 nmol/L
TrisHCL, pH 7.6, 3 mol/L NaCl, 1% Tween 20), and the
tissues were incubated at 55°C for 20 min in stringent
wash solution. The horseradish peroxidase labelled anti-
body (SA-HRP) (GenPoint System from DAKO) was
immediately applied on the tissues and incubated for 15
min in a humidifier chamber. The sections were washed
in TBST 1X. Biotinyl tyramide was applied to the tissue
sections for signal amplification for 15 min at room tem-
perature, and washed in TBST. A second SA-HRP step was
carried out and the color reaction was developed with
0.06% diaminobenzidine (DAB) in 3% H2O2. Finally, the
slides were washed, haematoxylin/counterstained, dehy-
drated in graded ethanol and mounted. Negative controls
for ISH were carried out with the sense probes or with a
treatment with RNAse solution (100 mg/ml for 30 min at
37°C) prior ISH. Cells were scored as positive for MMP11,
MMP12 and CTSF when they showed cytoplasmic expres-
sion under the light microscope. Only the neoplastic
region of each tissue section was evaluated. To asses the
stained cytoplasm, the slides were viewed at 40× magnifi-
cation. The positivity of cells in each tissue section was
estimated by the mean signal intensity, where: (0) posi-
tive staining present in at least half of the studied tissue,
(1) positive staining of half of the tumor area, and (2)
when all tissue had positive staining. The slides were eval-
uated blindly by three independent observers.
Immunohistochemical assays (IHC)
Briefly, the tissue sections were deparaffinized and rehy-
drated in a graded ethanol series. Endogenous peroxidase
inactivation was carried out as described in ISH, and the
slides were preincubated with DAKO Protein Block Serum
free medium Cat X0909 (DAKO, Carpinteria, CA) for 30
min at 37°C to prevent non specific immunoreaction.
Excess medium was decanted ant tissues were incubated
with the primary antibody as follows: MMP 11 (Biomeda,
Cat V10221, Lot 10441, 1:100), MMP12 (R&D Systems,
Cat MAB917, Lot AGEO22051. 1:100) at 37°C for 30
min, after which, DAKO Envision System Peroxidase
(DAKO) was applied and the slides were counterstained
with hematoxylin. As for the In situ hybridization, only
cells in the neoplastic region of each tumor were evaluated
and only when staining for the two proteins were present
in the cytoplasm. A rough scoring was done to quantitate
the intensity of the staining by three authors (GVO, MSV
and PPS). Levels of MMP11 and MMP12 expression in tis-
sue sections were scored under the light microscope.
Scores were obtained by estimating mean signal intensity
(scale 0 to 2). Scoring was achieved as for ISH. After the
examination of the slides by the three independent
observers, a global agreement regarding the results was
reached.
Results
Changes in cDNA expression in CC
Initial analysis of the three normal cervical tissues by
limma and marray package showed that the expression
profiles were similar. Thus, the data of the histologically
normal tissue samples were pooled to generate a mean
normal tissue array. Data from the cell lines and tissue
arrays were compared with the mean normal tissue arrays.
The frequency of increased or decreased gene expression
changes was determined by comparing the average nor-
mal tissue array with each of the cell lines and tissue
arrays. The cut-off values were 4 fold over the normal for
up-regulated, and -1 fold for down-regulated or sup-
pressed genes. Fourteenl genes were overexpressed
(TIMP1, Integrins alpha 1 and 4, cadherin 2 and 11, Cathep-
sins F, B L2, MMP 9, 10 11 and 12), and 10 genes were
down-regulated (Cathepsin S, L, H and C, Cadherins 3 and
4, TIMP3, MMP 13, Elastase 2 and Integrin beta 8, Table 1).
Verification of cDNA expression array results by RT-PCR
The gene expression profile findings in cDNA arrays were
confirmed by endpoint RT-PCR with densitometry for
selected genes (CTSF, MMP11, MMP12, and β -actin; Fig.BMC Cancer 2005, 5:68 http://www.biomedcentral.com/1471-2407/5/68
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1). In general, these analyses showed significant results
consistent with those obtained by cDNA arrays. All 8 sam-
ples investigated by means of cDNA arrays showed
increased  CTSF  expression, and in line with this, the
tumor band intensities in agarose gels, as compared with
the control band intensity, were increased from an average
of 1.2 to 7 fold in all tumors for CTSF in the RT-PCR anal-
yses. All samples studied by cDNA microarray analysis
had increased MMP11 expression, and had a mean of 6
fold increased expression by RT-PCR. The greatest differ-
ence between the two methods was found in MMP12
expression. All samples studied showed increased MMP12
expression by cDNA array analysis and RT-PCR. All com-
parisons were statistically significant.
ISH was performed on HSIL and CC cases. A strong focal
signal (+++) was observed in all CC for the three genes
with 90% and 100% of positive. The number of positive
cells present in CC (+++) was higher than in HSIL (++).
CTSF was expressed in 90%, MMP11 in 90%, and MMP12
in 90% of HSIL studied samples in the tissue array. ALL
HSIL showed numerous positive cells for the three tran-
scripts studied. (Fig. 2C, G and 2K; Table 2). In most HSIL
MMP11, MMP12 and CTS staining was seen exclusively in
the epithelium. The number of positive cells in HSIL was
higher than in LSIL (++, +). All three genes were stained in
90% of LSIL (+) samples, while the signal was weaker or
undetectable in histological normal cervical tissues (Table
2, Fig. 2). H&E staining at higher magnification in an adja-
cent tissue slice revealed that the expression of CTS,
MMP11 and MMP12 was usually confined to the cyto-
plasm of a subset of epithelial tumor cells with morpho-
logical features of squamous differentiation. Almost all
samples showed heterogeneous staining along the tumor,
with a few cases showing a stronger reaction in basal layer
cells. No staining was observed in the adjacent stroma.
By immunostaining, the MMP11 and MMP12 proteins
were present only in the cytoplasm. There was a strong
correlation between ISH and IHC positive reactions. All
CC samples had a large number of positive cells (+++, ++)
for both proteins, the number of positive cells was lower
in HSIL (+++, ++). As seen with ISH, LSIL staining was
lower than in HSIL (+) and none of the normal tissues
stained for any of the studied proteins (Table 2, Figure 3).
Immnunostaining was heterogeneous in CC and in HSIL,
whereas in LSIL the staining was preferentially seen on the
basal epithelial cells. No staining was observed in the
adjacent stroma.
Discussion
To identify novel genes that could be associated with the
development CC, we screened a cDNA-based gene expres-
sion array of more than 8000 genes. From those genes
Table 1: Summary of altered gene expression in cervical cancer by cDNA array. Ratio (T/N), intensity ratio of the corresponding 
signals between tumor and normal cervical tissue.
Gene Name Unigene Locus Hela/n CaLO/n INBL/n SiHa/n CaSki/n T07/n T31/n T64/n
tissue inhibitor of metalloproteinase 1 Hs.446641 Xp11.3 7 4 4 3 4 4 4 4
integrin, alpha 9 Hs.222 3p21.3 7 6 3 4 3 4 4 3
cadherin 2, type 1, N-cadherin Hs.334131 18q11.2 6 4 4 5 4 5 4 6
cathepsin L2 Hs.87417 9q22.2 9 5 4 4 4 4 4 4
matrix metalloproteinase 12 Hs.1695 11q22.3 5 9 8 9 6 5 4 5
integrin, alpha 4 Hs.145140 2q31 8 3 5 4 3 4 5 4
serine B member 9 Hs.104879 6p25.2 5 4 4 5 4 3 4 4
serine, proteinase inhibitor, clade B member 3 Hs.227948 18q21.3 6 4 4 5 4 4 4 3
cathepsin B Hs.297939 8p22 6 4 3 5 5 4 4 4
cathepsin F Hs.11590 11q13 8 8 6 7 6 5 5 5
matrix metalloproteinase 10 Hs.2258 11q22 7 5 5 3 4 4 4 5
matrix metalloproteinase 11 (stromelysin 3) Hs.143751 22q11.23 6 8 6 6 6 5 5 5
matrix metalloproteinase 9 Hs.151738 20q13.12 5 6 5 4 4 5 4 3
cadherin 11, type 2 Hs.443435 16q22.1 6 3 3 3 4 5 5 4
cathepsin S Hs.181301 1q21 0 1 1 0 1 1 0 1
cathepsin L Hs.418123 9q21.33 0 0 1 1 1 0 0 1
cathepsin H Hs.114931 15q25.1 0 1 0 1 0 0 1 0
cathepsin C Hs.128065 11q14.2 1 0 1 0 1 1 1 0
matrix metalloproteinase 13 Hs.2936 11q22 0 0 0 1 0 1 0 0
tissue inhibitor of metalloproteinase 3 Hs.245188 22q12.3 0 1 0 1 1 1 1 0
cadherin 3, type 1, P-cadherin (placental) Hs.191842 16q22.1 0 1 1 0 0 1 0 1
cadherin 4, type 1, R-cadherin (retinal) Hs.376792 20q13.3 1 0 1 0 1 1 0 1
integrin, beta 8 Hs.355722 7p21.1 0 0 0 1 1 0 0 1
elastase 2, neutrophil Hs.99863 19p13.3 0 1 0 0 1 0 0 0BMC Cancer 2005, 5:68 http://www.biomedcentral.com/1471-2407/5/68
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Relative mRNA expression levels of CTSF, MMP11 and MMP12 in cervical tumors detected by RT-PCR Figure 1
Relative mRNA expression levels of CTSF, MMP11 and MMP12 in cervical tumors detected by RT-PCR. One hundred of total 
RNA was employed for RT-PCR experiments. The used samples were; line a) positive control, line b) negative control, line 1) 
normal HPV- tissue #N07, 2) normal HPV- tissue #N11, 3) normal HPV- tissue #N20, 4) normal HPV- tissue #N23, 5) HeLa, 
6) CaLO, 7) INBL, 8) CaSki, 9) SiHa, 10) tumoral sample #T04, 11) tumoral sample #T24, 12) tumoral sample #T43, 13) 
tumoral sample #T45, 14) Tumoral sample T63. A 100 bp ladder was used as molecular weight marker. Values in the graph are 
presented as ratio of densitometric readings of samples to corresponding beta actin samples.
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In situ hybridization of cervical tissue microarrays with CTSF, MMP11 and MMP12 probes Figure 2
In situ hybridization of cervical tissue microarrays with CTSF, MMP11 and MMP12 probes. A) Breast cancer (as positive control 
of CTSF), B) normal cervical epithelium negative for CTSF, C) HSIL with positive immunostaining, D) CC tissue positive for 
CTSF hybridization, E) Breast cancer (as positive control for MMP11), F) normal cervical epithelium, negative for MMP11 
hybridization, G) as in C, HSIL positive for MMP11 hybridization, H) positive hybridization for MMP11 in CC, I) Breast cancer 
as positive control for MMP12, J) MMP12 negative hybridization in normal epithelium, K) as in C and G HSIL positive for 
MMP12, and L) Positive hybridization for MMP12 in CC. Original magnifications were 40 X for A, C, E, I and L; and 10X were 
used for B, D, F, G, H, J, and K.
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found to be significantly upregulated by gene expression
analysis, we initially focused on 24 because of their possi-
ble involvement in invasiveness and metastasis, 14 of
these genes were found to be expressed only in tumor tis-
sue. The present report constitutes the detailed analysis of
three such genes: MMP11 MMP12 and cathepsin F.
Overexpression of CTSF, MMP11 and MMP12 in CC was
confirmed by means of end point RT-PCR. All transcripts
were detected in CC, suggesting that these genes are essen-
tially active in the invasive processes of cervical cancer. It
is important to note that by ISH these genes were found to
be progressively expressed through different stages of cer-
vical carcinogenesis, except for two cases of HSIL, one
probable reason of this could be: a possible regression of
the disease.
Many normal biological processes, including reproduc-
tion, fetal development and wound healing, are critically
dependent on controlled degradation of extracellular
matrix (ECM). However, excessive degradation of matrix
components also occurs in pathologic tissue destruction
such as cancer [32]. MMP11 expression in the immediate
vicinity or within cancer cells has been associated with
some human carcinomas and it is a consistently active
partner of invading cancer cells. Its function differs
throughout cancer progression, where in can be a tumor
enhancer or a repressor in a number of processes leading
to local or distal invasion and promoting cancer survival
in the stromal environment [33]. We found expression of
MMP11 in cervical precancerous lesions but not in histo-
logical normal cervix tissues. MMP11 expression was sig-
nificantly higher in invasive carcinomas. Positive
immunoreaction was detected in the cytoplasm of cervix
epithelium tumor cells, differing from other tumor tis-
sues, where MMP11 expression is restricted to stromal
cells that surround the neoplastic area[34].
MMP11 expression has been reported in pre-invasive
bronchial lesions and in carcinomas. MMP11 expression
in bronchial lesions starts in dysplasia and carcinoma in
situ, increasing in invasive lesions, as it appears to occur in
CC. Expression of MMP11 in intraepithelial squamous
lesions suggest that, as in squamous lung carcinomas, it
could be related to progression of phenotypic alterations
acquired early during the malignant transformation path-
way of cervical epithelium and it is maintained after inva-
sion[35]. It has been previously reported that when
MMP11 is increased in tumorigenesis, this is not due to
increased neoangiogenesis or cancer cell proliferation, but
from a decrease of cancer cell death by apoptosis and
necrosis. These data suggest that MMP11 could play dif-
ferent roles trough distinct pathways at different stages of
cervical tumor development and progression. This needs
to be further studied in CC.
The biological role of MMP12 in tumor progression is not
clearly understood but it is thought to be involved in the
degradation of components of the basement mem-
brane[36]. Moreover, previous reports have shown that
transformed epithelial cells in skin and vulvar cancers
express MMP12 and such expression correlates with epi-
thelial dedifferentiation and invasive aggressiveness. In
oral verrucous and squamous cell cancer, the absence of
MMP12 from epithelial cells has been reported to be a
marker of good prognosis in non-invasive oral
carcinoma[37].
Table 2: Summary of the In situ hybridizations and immunohistochemical stainings results of cervical tissue microarrays.
% Positivity in ISH
CTSF MMP11 MMP12
Total of cases - (+) (++) (+++) - (+) (++) (+++) - (+) (++) (+++)
Normal tissues 15 14 1 0 0 13 2 0 0 13 2 0 0
L S I L 1 0 1 9 00 1 9 00 1 9 00
H S I L 1 0 1 1 80 1 2 70 1 2 70
CC tissues 15 0 0 0 15 0 0 0 15 0 0 0 15
% Positivity in IHC
MMP11 MMP12
Total of cases - (+) (++) (+++) - (+) (++) (+++)
Normal tissues 15 15 0 0 0 15 0 0 0
LSIL 10 0 10 0 0 0 9 1 0
H S I L 1 0 0 2 80 0 0 80
CC tissues 15 0 0 5 10 0 0 1 14BMC Cancer 2005, 5:68 http://www.biomedcentral.com/1471-2407/5/68
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Immunohistochemical detection of MMP11 and MMP12 by cervical tissue microarrays Figure 3
Immunohistochemical detection of MMP11 and MMP12 by cervical tissue microarrays. A) Breast cancer sample (as positive 
control for MMP11 staining), B) negative control; a CC sample without primary antibody, C) one normal cervical tissue show-
ing negative staining for MMP11, D) LSIL which presents positive immunostaining for MMP11, E) HSIL positive staining for 
MMP11 F) a CC showing positive immunoreaction for MMP11, G) Positive control for MMP12, H) as in B, negative control for 
MMP12, I) normal cervical tissue shows negative immunostaining for MMP12, J) LSIL showing positive immunoreaction for 
MMP12, K) HSIL showing immunodetection for MMP12 and L) a CC showing positive immunoreaction for MMP12. Original 
magnifications were 40 X for A, C, D, E, F, G, J, and K; and 10X were used for B, H, I, and L.
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MMP12 expression in cervical dysplasias and carcinomas
has not been previously reported. Expression of MMP12
was detected in most LSIL, HSIL, and all CC samples, but
it was absent in normal tissues, probably meaning that
this protein is closely involved in early stages of transfor-
mation and invasion. By immunohistochemical assays,
MMP11 and 12 proteins were detected in LSIL and HSIL
with similar patterns as in ISH. Staining was mainly
detected in basal cells, probably indicating their degrada-
tive and invasive capability.
Although only little data are available on CTSF, analysis of
its expression in humans has revealed that it is present in
most normal tissues, suggesting a general role for this
enzyme in lysosomal function in all cell types. However,
CTSF expression levels in normal tissues exhibit a wide
variability depending on the tissue type. Several human
cancer cell lines have increased expression of CTSF com-
pared to its normal counterpart. This suggests that this
enzyme could play an important role in carcinogenesis.
Our results are in agreement with a previous study which
revealed high levels of CTSF in HeLa cells[38], but it has
not been described in cervical cancer. Due to a lack of
availability of a specific CTSF antibody, we did not per-
form IHC assays for this protein. However, by means of
ISH, CTSF expression pattern resembles that of MMP11
and 12.
Finally, two more genes found to be overexpressed in this
study were MMP9 and TIMP1 (tissue inhibitor of metallo-
proteinase 1, Table 1). Interestingly, MMP9 and MMP2
up-regulation in cervical cancer was previously reported
[33-43] and the combined overexpression of MMP9,
MMP11 and TIMP1 has been associated with the invasive
features of some cancers[44]. These proteins are clearly
associated with CC and their overxpression in this work
validates the approach employed.
Conclusion
In conclusion, our results show that CTSF, MMP11 and 12
are expressed in dysplastic and tumoral epithelial cells
suggesting all of these proteins could be used as "poten-
tial" progression markers for cervical cancer. The under-
standing of the role, if any, of these proteins in the
pathogenesis of CC deserves further studies.
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